Back to JENNISON ASSOCIATES LLC JENNISON ASSOCIATES LLC

PTGXPTGX
7 quarters

Position history for JENNISON ASSOCIATES LLCJENNISON ASSOCIATES LLC's holdings in PROTAGONIST THERAPEUTICS INC

Yes. Jennison Associates holds 1,151,681 shares of PTGX (Protagonist Therapeutics), worth $141.2M, as of its Q2 2026 13F filing. It increased the position by 79,670 shares (+7.4%) from Q1 2026. Jennison Associates has held PTGX since Q4 2025, across 3 quarterly 13F filings. PTGX is 0.1% of Jennison Associates' reported 13F portfolio.

Current Value

$141.2M

Current Shares

1.2M

Total Value Change

+$131.3M

Total Shares Change

+722,743

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.2M
+7.4%
$141.2M0.1%$122.58
33
2026-Q1
Increased
1.1M
+223.7%
$113M0.1%$105.40
48
2025-Q4
New
331,164
-
$28.9M0.0%$87.34
40
2025-Q2
Exited
0
-100.0%
$00.0%$55.27
0
2025-Q1
New
18,317
-
$885,8100.0%$48.36
34
2023-Q2
Exited
0
-100.0%
$00.0%$27.62
0
2023-Q1
New
428,938
-
$9.9M0.0%$23.00
38

Other major holders of PTGX: BlackRock, Inc., FARALLON CAPITAL MANAGEMENT, L.L.C.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used